Fina Barouch, MD
Retina Specialist · Peabody, MANPI 1386628501
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $454 and has fallen 92.5% since, to $34 in 2025. That places this record below the midpoint for retina specialist clinicians in MA, where the typical reported total is $806.
Across 11 payments — averaging $69.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$182
- Astellas Pharma US Inc$148
- Regeneron$124
- Genentech USA, Inc.$115
- Iridex Corporation$70
- Optovue, Inc.$63
- plus $66 from 3 others
What the payments were for
- Food & beverage$73796%
- Education$324%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 2 | $182 |
| Astellas Pharma US Inc | 2 | $148 |
| Regeneron | 1 | $124 |
| Genentech USA, Inc. | 1 | $115 |
| Iridex Corporation | 1 | $70 |
| Optovue, Inc. | 1 | $63 |
| AbbVie | 1 | $34 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$167
- VABYSMO$115
How this compares
$769 in reported general payments places this provider in the 45th percentile of 26 retina specialist providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 31 | $4,921 |
| Prednisolone Acetate | 68 | $3,704 |
| Difluprednate | 18 | $3,115 |
| Ketorolac Tromethamine | 44 | $1,227 |
| Timolol Maleate | 26 | $934 |
| Brimonidine Tartrate | 24 | $781 |
| Dorzolamide Hcl | 25 | $404 |
| Ofloxacin | 29 | $311 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $286 |
| Latanoprost | 48 | $259 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Peabody
- Jeffrey HeierBoston$1.5M
- Alyse RichardDartmouth$37K
- Andre WitkinBoston$23K
- Chirag ShahBoston$14K
- Elite Bor-ShavitLancaster$11K
- Rebecca SoaresSpringfield$10K
- Brian BalliosBoston$3K
- Brad BakerWorcester$2K
- David ReedPlymouth$2K
- Ilya LeskovBoston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.